DNA vaccines against cytomegalovirus: current progress

The development of a vaccine for the prevention of primary cytomegalovirus (CMV) infection is a major public health priority. Live attenuated virus, recombinant viral vector, recombinant protein and peptide vaccines have been studied as potential vaccine candidates. In recent years, DNA vaccination...

Full description

Saved in:
Bibliographic Details
Published in:International Journal of Antimicrobial Agents 2002-03, Vol.19 (3), p.169-172
Main Author: Temperton, N.J.
Format: Article
Language:English
Subjects:
Animals
Antibody
Antigens, Viral - genetics
Antigens, Viral - immunology
Biological and medical sciences
CTL
Cytomegalovirus
Cytomegalovirus - genetics
Cytomegalovirus - immunology
Cytomegalovirus Infections - immunology
Cytomegalovirus Infections - prevention & control
DNA vaccines
Genes, Viral
Humans
Immunomodulators
Medical sciences
Pharmacology. Drug treatments
Protection
Viral Vaccines - genetics
Viral Vaccines - immunology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The development of a vaccine for the prevention of primary cytomegalovirus (CMV) infection is a major public health priority. Live attenuated virus, recombinant viral vector, recombinant protein and peptide vaccines have been studied as potential vaccine candidates. In recent years, DNA vaccination strategies have been developed for many pathogens, including CMV. This review aims to bring together many aspects of this relatively new vaccine technology as applied to current research into the development of vaccines against CMV.
ISSN:0924-8579
1872-7913
DOI:10.1016/S0924-8579(01)00492-7